2026-04-11T09:44:06Z
https://pub.unibl.org/oai
oai:pub.unibl.org:40912
2024-06-12T14:24:19Z
FRIO162 Comparable Safety and Immunogenecity and Sustained Efficacy after Transition To SB2 (An Infliximab Biosimilar) vs Ongoing Infliximab Reference Product In Patients with Rheumatoid Arthritis: Results of Phase III Transition Stud
JS Smolen
creator
JY Choe
creator
Ненад Продановић
creator
I Staykov
creator
E Dokoupilova
creator
A Baranauskaite
creator
R Yatsyshyn
creator
M Mekić
creator
W Porawska
creator
H Ciferska
creator
K Jedrichovicz-Rosiak
creator
A Zelinska
creator
Z Lee
creator
YH Rho
creator
Academic Article
text
/unibl/sci/idNaucniRad:25131
ANNALS OF THE RHEUMATIC DISEASES
0003-4967
https://pub.unibl.org/s/cir/item/40912
2016
40912